Patents by Inventor Qingjie Liu
Qingjie Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190119245Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR4 or N; R1, R2, R3, R4, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: ApplicationFiled: February 1, 2018Publication date: April 25, 2019Inventors: Qingjie Liu, Scott Hunter Watterson, John E. Macor, Khehyong Ngu, Saleem Ahmad
-
Patent number: 10266491Abstract: Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein Q, R1a, R1b, R2a, R2b, R3, R4, R5a, R5b, R6a, R6c, R7a, R7b, R7c, and R7d are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: GrantFiled: October 23, 2015Date of Patent: April 23, 2019Assignee: Bristol-Myers Squibb CompanyInventors: Saleem Ahmad, Douglas G. Batt, Qingjie Liu, John E. Macor, Joseph A. Tino, Scott Hunter Watterson, Satheesh Kesavan Nair, Tarun Kumar Maishal
-
Patent number: 10214537Abstract: Disclosed are compounds of Formula (I) or a salt thereof; wherein: X is N or CH; Q1 is: (i) Cl, Br, I, —CN, —CH3, or —CF3; (ii) a 5-membered heteroaryl selected from pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, and thiadiazolyl; (iii) a 6?membered heteroaryl selected from pyridinyl, pyridazinyl, and pyrimidinyl; or (iv) a bicyclic heteroaryl selected from indolyl, pyrrolopyridinyl, pyrazolopyridinyl and benzo[d]oxazolyl; wherein each of said 5-membered, 6-membered, and bicyclic heteroaryl is substituted with zero to 1 Ra and zero to 1 Rb; and R1, R2, R3, R4, R5, R6, Ra, and Rb are defined herein. Also disclosed are methods of using such compounds as modulators of PI3K, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.Type: GrantFiled: October 21, 2015Date of Patent: February 26, 2019Assignee: Bristol-Myers Squibb CompanyInventors: Rajeev S. Bhide, Douglas G. Batt, Robert J. Cherney, Lyndon A. M. Cornelius, Qingjie Liu, David Marcoux, James Neels, Michael A. Poss, Zheming Ruan, Qing Shi, Anurag S. Srivastava, Lan-ying Qin, Joseph A. Tino, Scott Hunter Watterson
-
Publication number: 20190023719Abstract: Disclosed are compounds of Formula (I) wherein: the two dotted lines represent either two single or two double bonds; Q is: R1 is F, Cl, —CN, or —CH3; R2 is Cl or —CH3; R3 is —C(CH3)2OH or —CH2CH2OH; Ra is H or —CH3; each Rb is independently F, Cl, —CH3, and/or —OCH3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: ApplicationFiled: September 25, 2018Publication date: January 24, 2019Inventors: Douglas G. Batt, Myra Beaudoin Bertrand, George V. De Lucca, Michael A. Galella, Soo Sung Ko, Charles M. Langevine, Qingjie Liu, Qing Shi, Anurag S. Srivastava, Joseph A. Tino, Scott Hunter Watterson
-
Patent number: 10106559Abstract: Disclosed are compounds of Formula (I) wherein: the two dotted lines represent either two single or two double bonds; Q is: R1 is F, Cl, —CN, or —CH3; R2 is Cl or —CH3; R3 is —C(CH3)2OH or —CH2CH2OH; Ra is H or —CH3; each Rb is independently F, Cl, —CH3, and/or —OCH3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: GrantFiled: November 10, 2017Date of Patent: October 23, 2018Assignee: Bristol-Myers Squibb CompanyInventors: Douglas G. Batt, Myra Beaudoin Bertrand, George V. Delucca, Michael A. Galella, Soo Sung Ko, Charles M. Langevine, Qingjie Liu, Qing Shi, Anurag S. Srivastava, Joseph A. Tino, Scott Hunter Watterson
-
Publication number: 20180265504Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.Type: ApplicationFiled: May 15, 2018Publication date: September 20, 2018Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, John S. Tokarski, Amit Kumar, Douglas G. Batt, Shuqun Lin, Chunjian Liu, Steven H. Spergel, Yanlei Zhang, Qingjie Liu
-
Patent number: 10000480Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.Type: GrantFiled: October 10, 2016Date of Patent: June 19, 2018Assignee: Bristol-Myers Squibb CompanyInventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, John S. Tokarski, Amit Kumar, Douglas G. Batt, Shuqun Lin, Chunjian Liu, Steven H. Spergel, Yanlei Zhang, Qingjie Liu
-
Publication number: 20180079758Abstract: Disclosed are compounds of Formula (I) wherein: the two dotted lines represent either two single or two double bonds; Q is: R1 is F, Cl, —CN, or —CH3; R2 is Cl or —CH3; R3 is —C(CH3)2OH or —CH2CH2OH; Ra is H or —CH3; each Rb is independently F, Cl, —CH3, and/or —OCH3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: ApplicationFiled: November 10, 2017Publication date: March 22, 2018Inventors: Douglas G. Batt, Myra Beaudoin Bertrand, George V. Delucca, Michael A. Galella, Soo Sung Ko, Charles M. Langevine, Qingjie Liu, Qing Shi, Anurag S. Srivastava, Joseph A. Tino, Scott Hunter Watterson
-
Patent number: 9920031Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR4 or N; R1, R2, R3, R4, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: GrantFiled: May 30, 2017Date of Patent: March 20, 2018Assignee: Bristol-Myers Squibb CompanyInventors: Qingjie Liu, Scott Hunter Watterson, Saleem Ahmad
-
Publication number: 20180002358Abstract: There are described ROR? modulators of the formula (I), and formula (II) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: ApplicationFiled: September 12, 2017Publication date: January 4, 2018Inventors: Jingwu Duan, T.G. Murali Dhar, David Marcoux, Qing Shi, Douglas G. Batt, Qingjie Liu, Robert J. Cherney, Lyndon A.M. Cornelius, Anurag S. Srivastava, Myra Beaudoin Bertrand, Carolyn A. Weigelt
-
Publication number: 20170362176Abstract: Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein Q, R1a, R1b, R2a, R2b, R3, R4, R5a, R5b, R6a, R6c, R7a, R7b, R7c, and R7d are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: ApplicationFiled: October 23, 2015Publication date: December 21, 2017Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Saleem Ahmad, Douglas G. Batt, Qingjie Liu, John E. Macor, Joseph A. Tino, Scott Hunter Watterson
-
Publication number: 20170355707Abstract: Disclosed are compounds of Formula (I) or a salt thereof; wherein: X is N or CH; Q1 is: (i) Cl, Br, I, —CN, —CH3, or —CF3; (ii) a 5-membered heteroaryl selected from pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, and thiadiazolyl; (iii) a 6?membered heteroaryl selected from pyridinyl, pyridazinyl, and pyrimidinyl; or (iv) a bicyclic heteroaryl selected from indolyl, pyrrolopyridinyl, pyrazolopyridinyl and benzo[d]oxazolyl; wherein each of said 5-membered, 6-membered, and bicyclic heteroaryl is substituted with zero to 1 Ra and zero to 1 Rb; and R1, R2, R3, R4, R5, R6, Ra, and Rb are defined herein. Also disclosed are methods of using such compounds as modulators of PI3K, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.Type: ApplicationFiled: October 21, 2015Publication date: December 14, 2017Inventors: Rajeev S. Bhide, Douglas G. Batt, Robert J Cherney, Lyndon A.M. Cornelius, Qingjie Liu, David Marcoux, James Neels, Michael A. Poss, Zheming Ruan, Qing Shi, Anurag S. Srivastava, Lan-ying Qin, Joseph A. Tino, Scott Hunter Watterson
-
Patent number: 9815859Abstract: There are described ROR? modulators of the formula (I), and formula (II) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: GrantFiled: May 6, 2016Date of Patent: November 14, 2017Assignee: Bristol-Myers Squibb CompanyInventors: Jingwu Duan, T. G. Murali Dhar, David Marcoux, Qing Shi, Douglas G. Batt, Qingjie Liu, Robert J. Cherney, Lyndon A. M. Cornelius, Anurag S. Srivastava, Myra Beaudoin Bertrand, Carolyn A. Weigelt
-
Patent number: 9802915Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR4 or N; R1, R2, R3, R4, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: GrantFiled: November 17, 2016Date of Patent: October 31, 2017Assignee: Bristol-Myers Squibb CompanyInventors: Qingjie Liu, Scott Hunter Watterson, Saleem Ahmad, Andrew J. Tebben
-
Publication number: 20170283438Abstract: Disclosed are compounds of Formula (I) wherein: the two dotted lines represent either two single or two double bonds; Q is: R1 is F, Cl, —CN, or —CH3; R2 is Cl or —CH3; R3 is —C(CH3)2OH or —CH2CH2OH; Ra is H or —CH3; each Rb is independently F, Cl, —CH3, and/or —OCH3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: ApplicationFiled: June 16, 2017Publication date: October 5, 2017Inventors: Douglas G. Batt, Myra Beaudoin Bertrand, George V. Delucca, Michael A. Galella, Soo Sung Ko, Charles M. Langevine, Qingjie Liu, Qing Shi, Anurag S. Srivastava, Joseph A. Tino, Scott Hunter Watterson
-
Publication number: 20170260160Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR4 or N; R1, R2, R3, R4, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: ApplicationFiled: May 30, 2017Publication date: September 14, 2017Inventors: Qingjie Liu, Scott Hunter Watterson, Douglas G. Batt, Saleem Ahmad, Myra Beaudoin Bertrand, Hua Gong, Weiwei Guo, John E. Macor, Khehyong Ngu, Andrew J. Tebben, Joseph A. Tino
-
Patent number: 9714234Abstract: Disclosed are compounds of Formula (I); and salts thereof, wherein: Formula (II); Q is: R1 is —C(CH3)2OH, —NHC(=0)C(CH3)3, —N(CH3)2, or —CH2Rd; R2 is CI or —CH3; R3 is H, F, or —CH3; Ra is H or —CH3; Rb is H, F, CI, or —OCH3 Rc is H or F; and Rd is —OH, —OCH3, —NHC(=0)CH3, or fORMULA (III), Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: GrantFiled: June 25, 2014Date of Patent: July 25, 2017Assignee: Bristol-Myers Squibb CompanyInventors: Soo Sung Ko, Douglas G Batt, Myra Beaudoin Bertrand, George Delucca, Charles M. Langevine, Qingjie Liu, Anurag S. Srivastava, Scott Hunter Watterson
-
Patent number: 9688629Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR4 or N; R1, R2, R3, R4, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: GrantFiled: October 23, 2015Date of Patent: June 27, 2017Assignee: Bristol-Myers Squibb CompanyInventors: Qingjie Liu, Scott Hunter Watterson, Saleem Ahmad
-
Publication number: 20170066740Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR4 or N; R1, R2, R3, R4, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: ApplicationFiled: November 17, 2016Publication date: March 9, 2017Inventors: Qingjie Liu, Scott Hunter Watterson, Saleem Ahmad, Andrew J. Tebben
-
Publication number: 20170022192Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.Type: ApplicationFiled: October 10, 2016Publication date: January 26, 2017Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, John S. Tokarski, Amit Kumar, Douglas G. Batt, Shuqun Lin, Chunjian Liu, Steven H. Spergel, Yanlei Zhang, Qingjie Liu